GlassScriptPhysician profile
Kristen Slade
NPI 1144995242
$957.00
in general payments reported to CMS, 2019-2025
20 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $88.81 · 2023: $343 · 2024: $174 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $792 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $792.19 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $292.13 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.06 | 2022-2023 | |
| Becton, Dickinson and Company | $76.00 | 2023 | Bd Phaseal, Bd Introsyte |
| Novo Nordisk INC | $55.67 | 2023 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $43.33 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Sumitomo Pharma America, INC. | $40.80 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.54 | 2022-2025 | Jardiance |
| Lilly USA, LLC | $39.41 | 2025 | Jardiance, Mounjaro |
| Sunovion Pharmaceuticals INC. | $36.96 | 2022 | |
| Pfizer INC. | $34.21 | 2023-2024 | |
| Mylan Specialty L.P. | $24.50 | 2024 | Yupelri |
| Xeris Pharmaceuticals, INC. | $23.00 | 2023 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $19.19 | 2023 | Sapien 3 Ultra Resilia |
| Verona Pharma, INC. | $18.58 | 2025 | Ohtuvayre |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.24 | 2025 | Caplyta |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $17.14 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $16.42 | 2024 | Voquezna |
| Amgen INC. | $15.61 | 2024 | Prolia, Evenity |
| Merck Sharp & Dohme LLC | $14.15 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.06 | 2023 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Slade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.